The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is setting the stage for ...

Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies ​are expected to go public amid a ...

The Dow Jones Industrial Average and other major stock indexes reversed higher around noon Friday, as Wall Street looked ...

GALVESTON, TX / ACCESS Newswire / January 12, 2026 / Callan JMB Inc. (NASDAQ:CJMB), a premier provider of vertically ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

The VCs surveyed invest in various companies, including early-stage startups and large, publicly traded firms. Respondents pointed to Most Favored Nation-style drug price setting policies, the ...

The biotech sector has been one of the market's laggards for several years now, and 2025 has been no different, at least on the surface. Year-to-date, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Despite alarming federal budget cuts that stand to potentially harm the ...

Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path ...

Fortress Biotech amended a credit agreement to extend its maturity. The stock rose 4.8% to $4.40 in after-hours trading Monday. Par Technology was selected to be Papa John's International's new ...